Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up. The study design included both open-label continuation and randomized withdrawal phases, providing a rigorous look at both short- and longer-term outcomes. Results from trials like this contribute meaningful clinical data toward understanding whether standardized cannabis-based medicines can serve as a viable option for patients who have not found adequate relief from conventional treatments.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based therapy in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and significant adverse effect profiles. The large sample size (820 participants), double-blind design, and 6-month extended follow-up period establish the level of evidence necessary to inform clinical decision-making and potentially expand treatment options for patients who fail or cannot tolerate conventional analgesics. Given the opioid crisis and limitations of existing therapies, efficacy and safety data from this trial could reshape pain management guidelines and provide an evidence-based alternative for a substantial patient population with unmet therapeutic needs.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial adds meaningful data to the limited evidence base for cannabis-derived therapies in chronic low back pain, a condition where current pharmaceutical options remain suboptimal. While the study’s size and design represent a significant investment in rigorous evaluation, clinicians should note that the abstract provided is incomplete, preventing full assessment of efficacy outcomes, effect sizes, safety signals, and the critical question of whether benefits justify switching from or combining with established multimodal approaches. The heterogeneity of cannabis preparations, variable cannabinoid profiles across batches, and individual differences in metabolism mean that even positive results from VER-01 may not generalize to other full-spectrum extracts or patient populations. Given the ongoing regulatory uncertainty and the lack of standardized dosing or quality assurance in most cannabis products, practitioners should consider this evidence within the broader context of guideline-recommended physical therapy, psychological interventions, and judicious use of conventional analgesics rather than viewing it as a standalone replacement. If your patients with refractory CL